SOPHiA GENETICS has closed a $77 million funding round led by Generation Investment Management, with participation from Idinvest Partners, alongside existing investors including Balderton Capital and Alychlo.
The Swiss company's platform, SOPHiA AI, enables healthcare professionals to make sense of complex genomic and radiomic data in order to better diagnose and treat patients, both for oncology and hereditary disorders. Sophia AI is used by 850 hospitals in 77 countries, and has supported the diagnosis of more than 300,000 patients.
The latest funding round, which brings total investment in the company up to $140 million, will be used to expand its activities, particularly in the US.
"SOPHiA GENETICS is a leader in the preventive and personalised medicine revolution, enabling the development of targeted therapeutics, thereby vastly improving health outcomes," said Lilly Wollman, co-head of Generation's Growth Equity team.